Novartis Chairman Joerg Reinhardt may be chatting with his colleagues at Roche. His company may want to work more closely with its hometown rival. But joining forces in a merger? No, thank you.
More than two years ago Roche CEO Severin Schwan picked the cancer drug MetMAb out of the pipeline as one of the company's top blockbuster prospects. But on Monday its oncology R&D arm at Genentech was forced to halt a Phase III combo study matching MetMAb with Tarceva in a failed effort to block metastasis in non-small cell lung cancer after an independent monitoring group flagged the attempt for futility.
After largely abandoning the field back in 1999, Roche is diving back into antibiotics, teaming up with Cambridge, U.K.'s Discuva to discover and develop new treatments for deadly infections using the biotech's novel platform.
Johnson & Johnson was cautiously lauded for its clinical trial data-sharing initiative, but Roche's project was pilloried. Now Novartis has joined its Swiss peer in rolling out an underwhelming transparency program.
As the biosimilar market takes shape, companies are gunning to produce copies of some of the world's top-selling drugs. And according to a new Moody's report, with their star products wearing targets on their backs, AbbVie, Amgen and Roche are most exposed to the new competition.
The BMJ and others spent years trying to get Roche to release Tamiflu data, and the criticism continued even after the Swiss pharma put in a new results-sharing policy. Now, Roche is facing a situation where sharing trial data may be the best way to clear up the effect of Avastin on brain cancer.
Should Avastin really join the small set of tools in the brain-cancer toolbox? With studies offering conflicting results, Roche and some outside researchers may share data to answer that question.
Roche's new extended partnership with Cancer Genetics will expand molecular diagnostic cancer testing in the Caribbean and Central America as part of a three-year deal.
Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.
In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...